This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

LYNK Pharma

Profile

Lynk Pharmaceuticals is a clinical-stage innovative drug discovery company dedicated to the treatment of cancer, autoimmune, and inflammatory diseases. Co-founded by senior drug discovery experts and executives from Pfizer, Merck, and Johnson & Johnson; the company has many decades of experience in the field of drug discovery. Driven by higher goals, Lynk aims to be a market leader in addressing unmet medical needs by developing innovative & differentiated therapies. Established in 2018, the company has attracted many international scientists and leaders. Lynk has also attracted investments from well-known investment institutions including Decheng Capital, Legend Capital, Lilly Asia Ventures and other investors. Lynk has established a promising R&D pipeline including a focused effort to develop isoform-selective JAK inhibitors (2nd generation JAKi) and tissue-restrictive JAK inhibitors (3rd generation JAKi) to deliver more effective and safer therapies. The company’s pipeline includes four 2nd and 3rd generation of JAK inhibitors in multiple Phase I and Phase II studies. The company expects to initiate 3 Phase III studies in 2023. Lynk has laid a solid foundation of commercialization by fostering a business collaboration with Simcere Pharmaceuticals in China and continues to work with EQRx closely for the global development of LNK01001. Lynk has won many awards: • The first prize of biomedical industry (start-up group) in the 7th China Innovation and Entrepreneurship Competition;2019 Frost & Sullivan China New Economy Award-Excellence in Innovation &The First KPMG China's Biotechnology Innovation 50 Enterprises;2021 Top 30 Small Molecule Drug Innovation Capability in China& Top 100 Biomedical Innovation Companies in China;2022 KPMG Top 50 Biotech Companies in China Future Medical Top 100 &Hangzhou Quasi-Unicorn Enterprise &Qipu Award – Top 10 Drug Innovation Seeds Lynk is looking for creative partnerships to develop the full potential of the pipeline